Autor: |
Zhuqing Shi, Hongjie Yu, Yishuo Wu, Xiaoling Lin, Quanwa Bao, Haifei Jia, Chelsea Perschon, David Duggan, Brian T. Helfand, Siqun L. Zheng, Jianfeng Xu |
Jazyk: |
angličtina |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
Cancer Medicine, Vol 8, Iss 6, Pp 3196-3205 (2019) |
Druh dokumentu: |
article |
ISSN: |
2045-7634 |
DOI: |
10.1002/cam4.2143 |
Popis: |
Abstract Background Genetic risk score (GRS) is an odds ratio (OR)‐weighted and population‐standardized method for measuring cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). We hypothesize that GRS is a valid tool for risk assessment of most common cancers. Methods Utilizing genotype and phenotype data from The Cancer Genome Atlas (TCGA) and Electronic Medical Records and Genomics (eMERGE), we tested 11 cancer‐specific GRSs (bladder, breast, colorectal, glioma, lung, melanoma, ovarian, pancreatic, prostate, renal, and thyroid cancer) for association with the respective cancer type. Cancer‐specific GRSs were calculated, for the first time in these cohorts, based on previously published risk‐associated SNPs using the Caucasian subjects in these two cohorts. Results Mean cancer‐specific GRS in the population controls of eMERGE approximated the expected value of 1.00 (between 0.98 and 1.02) for all 11 types of cancer. Mean cancer‐specific GRS was consistently higher in respective cancer patients than controls for all 11 types of cancer (P 1.5, respectively), significant dose‐response associations of higher cancer‐specific GRS with higher OR of respective type of cancer were found for nine types of cancer (P‐trend |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|